ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 478,43
-2,98%
Dow Jones
38 363,38
-0,73%
DAX
17 978,30
-1,56%
Brent Oil
82,51
0,65%
Bitcoin
66 654,14
-0,15%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kiniksa Pharmaceuticals Ltd (KNSA)

  7. Kiniksa Pharmaceuticals Ltd (KNSA) Actualités

KNSA

Kiniksa Pharmaceuticals (KNSA)

Kiniksa Pharmaceuticals Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KNSA
DateHeureSourceTitreSymboleSociété
05/06/202422h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
04/06/202422h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
29/05/202423h19Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
07/05/202422h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care ConferenceNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
23/04/202413h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
16/04/202422h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
02/04/202413h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Announces Development Indication for AbiprubartNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
05/03/202422h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
01/03/202423h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
28/02/202413h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
21/02/202422h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
14/02/202422h39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
04/01/202413h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Provides Corporate UpdateNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
02/01/202422h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
02/11/202321h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
31/10/202312h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
24/10/202322h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
10/08/202322h15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
25/07/202313h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
17/07/202314h00GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
08/06/202323h39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
07/06/202323h10Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
06/06/202322h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
04/05/202322h25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
02/05/202313h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
01/05/202322h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
08/03/202320h16Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
02/03/202322h26Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
28/02/202314h00GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
27/02/202322h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:KNSA

Dernières Valeurs Consultées

EU
ACA
Credit Agricole
COIN
BTCUSD
Bitcoin
NYSE
DIS
Walt Disney
EU
RNO
Renault
NYSE
MCD
McDonalds
EU
MC
Lvmh Moet Hennessy Louis...
EU
CS
Axa
USI
USTECH100
US Tech 100
EU
GLE
Societe Generale
EU
HO
Thales
EU
SGO
Cie de SaintGobain
NASDAQ
NVDA
NVIDIA
EU
DG
Vinci
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés